Redeye provides its initial take on MedCap’s Q1 2026 report, which came in broadly in line with our estimates for adjusted EBITA, though revenue was 6% below our forecast. We judge that the positives from the report include growth in Speciality Pharma with improved adj. EBITA margin and a record-high margin for Assistive Tech. The total organic growth was more in line with normal levels this quarter at 4%, in contrast to the recent relatively high organic growth rates in Q3-Q4 2025 (9%-10%).
LÄS MER
